PL1856135T3 - Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie - Google Patents

Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie

Info

Publication number: PL1856135T3
Authority: PL; Poland
Prior art keywords: prodrugs; pyrimidinediamine compounds; methods; intermediates; synthesizing
Prior art date: 2005-01-19

Application number

PL06718943T

Other languages

English (en)

Inventor

Rajinder Singh

Somasekhar Bhamidipati

Esteban Masuda

Valentino J Stella

Thomas Sun

Original Assignee

Rigel Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-19

Filing date

2006-01-19

Publication date

2010-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36295425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1856135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-19 Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc

2010-05-31 Publication of PL1856135T3 publication Critical patent/PL1856135T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)

PL06718943T 2005-01-19 2006-01-19 Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie PL1856135T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US64542405P	2005-01-19	2005-01-19
US65462005P	2005-02-18	2005-02-18
EP06718943A EP1856135B1 (en)	2005-01-19	2006-01-19	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PCT/US2006/001945 WO2006078846A1 (en)	2005-01-19	2006-01-19	Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Publications (1)

Publication Number	Publication Date
PL1856135T3 true PL1856135T3 (pl)	2010-05-31

Family

ID=36295425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06718943T PL1856135T3 (pl)	2005-01-19	2006-01-19	Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie

Country Status (28)

Country	Link
US (13)	US7449458B2 (pl)
EP (2)	EP1856135B1 (pl)
JP (2)	JP4801096B2 (pl)
KR (1)	KR101278397B1 (pl)
CN (1)	CN101115761B (pl)
AT (1)	ATE451381T1 (pl)
AU (1)	AU2006206458B2 (pl)
BR (1)	BRPI0606318B8 (pl)
CA (1)	CA2591948C (pl)
CY (2)	CY1109888T1 (pl)
DE (1)	DE602006010979D1 (pl)
DK (1)	DK1856135T3 (pl)
ES (1)	ES2337496T3 (pl)
FI (1)	FIC20200014I1 (pl)
HK (1)	HK1108896A1 (pl)
HU (1)	HUS2000011I1 (pl)
IL (1)	IL183890A (pl)
LT (1)	LTC1856135I2 (pl)
LU (1)	LUC00153I2 (pl)
MX (2)	MX2007007189A (pl)
NL (1)	NL301039I2 (pl)
NO (2)	NO339146B1 (pl)
NZ (1)	NZ555947A (pl)
PL (1)	PL1856135T3 (pl)
PT (1)	PT1856135E (pl)
RU (1)	RU2416616C2 (pl)
SI (1)	SI1856135T1 (pl)
WO (1)	WO2006078846A1 (pl)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en)	2002-07-29	2009-04-14	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP2251343A1 (en) *	2003-05-15	2010-11-17	Arqule, Inc.	Imidazothiazoles as p38-kinase-inhibitors
DK1656372T3 (da)	2003-07-30	2013-07-01	Rigel Pharmaceuticals Inc	2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
EP1763514A2 (en)	2004-05-18	2007-03-21	Rigel Pharmaceuticals, Inc.	Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006044869A1 (en) *	2004-10-19	2006-04-27	Arqule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB2420559B (en)	2004-11-15	2008-08-06	Rigel Pharmaceuticals Inc	Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
SI1814878T1 (sl)	2004-11-24	2012-06-29	Rigel Pharmaceuticals Inc	Spojine spiro-2,4-pirimidindiamina in njihova uporaba
PL1856135T3 (pl) *	2005-01-19	2010-05-31	Rigel Pharmaceuticals Inc	Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
US8227455B2 (en) *	2005-04-18	2012-07-24	Rigel Pharmaceuticals, Inc.	Methods of treating cell proliferative disorders
EP1883302A4 (en) *	2005-05-03	2009-05-20	Rigel Pharmaceuticals Inc	JAK KINASE HEMMER AND ITS USE
US20070203161A1 (en) *	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
JP5225079B2 (ja) *	2005-06-08	2013-07-03	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
CA2607901C (en)	2005-06-13	2016-08-16	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
ATE352714T1 (de) *	2005-06-17	2007-02-15	Magneti Marelli Powertrain Spa	Brennstoffeinspritzventil
US20090306028A1 (en) *	2005-10-31	2009-12-10	Payan Donald G	Compositions and methods for treating inflammatory disorders
US20100041678A1 (en) *	2005-10-31	2010-02-18	Rigel Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory disorders
US7713987B2 (en) *	2005-12-06	2010-05-11	Rigel Pharmaceuticals, Inc.	Pyrimidine-2,4-diamines and their uses
KR101411695B1 (ko)	2006-02-17	2014-07-03	리겔 파마슈티칼스, 인크.	자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
CA2642229C (en) *	2006-02-24	2015-05-12	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US7501430B2 (en) *	2006-04-17	2009-03-10	Arqule, Inc.	RAF inhibitors and their uses
CA2658506C (en)	2006-07-20	2016-01-26	Affinium Pharmaceuticals, Inc.	Acrylamide derivatives as fab 1 inhibitors
US8193197B2 (en) *	2006-10-19	2012-06-05	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2008061201A1 (en) *	2006-11-15	2008-05-22	Rigel Pharmaceuticals, Inc.	Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds
ES2380551T3 (es) *	2006-11-21	2012-05-16	Rigel Pharmaceuticals, Inc.	Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
WO2008118822A1 (en)	2007-03-23	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2008118823A2 (en) *	2007-03-26	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2009003136A1 (en) *	2007-06-26	2008-12-31	Rigel Pharmaceuticals, Inc.	Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
EP2183225A1 (en)	2007-07-17	2010-05-12	Rigel Pharmaceuticals, Inc.	Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US20090088371A1 (en) *	2007-08-28	2009-04-02	Rigel Pharmaceuticals, Inc.	Combination therapy with syk kinase inhibitor
PT2217241T (pt) *	2007-11-07	2018-06-11	Rigel Pharmaceuticals Inc	Granulação por via húmida utilizando um agente sequestrante de água
PT2265607T (pt) *	2008-02-15	2017-03-08	Rigel Pharmaceuticals Inc	Compostos de pirimidina-2-amina e sua utilização como inibidores de jak cinases
WO2009105675A1 (en) *	2008-02-22	2009-08-27	Rigel Pharmaceuticals, Inc.	Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis
BRPI0910921B1 (pt)	2008-04-16	2022-06-21	Portola Pharmaceuticals, Inc	Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
AU2009238590A1 (en)	2008-04-22	2009-10-29	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
AU2013205510A1 (en) *	2008-05-21	2013-05-16	Ariad Pharmaceuticals, Inc.	Phosphorous derivatives as kinase inhibitors
EA029131B1 (ru)	2008-05-21	2018-02-28	Ариад Фармасьютикалз, Инк.	Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en)	2008-06-27	2016-01-28	Celgene Avilomics Res Inc	Heteroaryl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102112446B (zh)	2008-07-28	2012-10-31	美国辉瑞有限公司	菲酮化合物、组合物及方法
US20110172217A1 (en) *	2008-09-05	2011-07-14	Shionogi & Co., Ltd.	Ring-fused morpholine derivative having pi3k-inhibiting activity
JP5616345B2 (ja)	2008-09-18	2014-10-29	オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	小胞モノアミン輸送体２のベンゾキノリン阻害剤
AU2009322158A1 (en) *	2008-12-05	2010-06-10	Arqule, Inc.	RAF inhibitors and their uses
TW201034675A (en)	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
SG172885A1 (en)	2009-01-23	2011-08-29	Rigel Pharmaceuticals Inc	Compositions and methods for inhibition of the jak pathway
AR076550A1 (es)	2009-05-06	2011-06-22	Portola Pharm Inc	Inhibidores de la janus tirosina kinasa (jak)
UA108077C2 (xx) *	2009-07-02	2015-03-25		Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
JP2012533567A (ja)	2009-07-17	2012-12-27	ライジェルファーマシューティカルズ，インコーポレイテッド	重水素化２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
AU2010281404A1 (en) *	2009-07-28	2012-02-09	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2011063241A1 (en)	2009-11-20	2011-05-26	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
ES2609040T3 (es)	2009-12-17	2017-04-18	Merck Sharp & Dohme Corp.	Aminopirimidinas como inhibidores de Syk
WO2011075560A1 (en)	2009-12-17	2011-06-23	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
EP2539347A2 (en) *	2010-02-24	2013-01-02	Auspex Pharmaceuticals, Inc.	Trimethoxyphenyl inhibitors of tyrosine kinase
JP6067550B2 (ja) *	2010-04-13	2017-01-25	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
ES2880622T3 (es)	2010-07-28	2021-11-25	Rigel Pharmaceuticals Inc	Composiciones y procedimientos para la inhibición de la ruta de JAK
BR112013003388A2 (pt)	2010-08-10	2016-07-12	Celgene Avilomics Res Inc	sal de besilato de um inibidor de btk
MY181898A (en)	2010-11-01	2021-01-12	Celgene Car Llc	Heterocyclic compounds and uses thereof
JP5956999B2 (ja)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	ヘテロアリール化合物およびその使用
JP5957003B2 (ja)	2010-11-10	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	変異体選択的ｅｇｆｒ阻害剤およびその使用
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2704572B1 (en)	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012154518A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Bipyridylaminopyridines as syk inhibitors
MX2013013090A (es)	2011-05-10	2013-12-16	Merck Sharp & Dohme	Aminopirimidinas como inhibidores de tirosina cinaza del bazo.
CA2834062A1 (en)	2011-05-10	2012-11-15	Merck Sharp & Dohme Corp.	Pyridyl aminopyridines as syk inhibitors
UY34072A (es)	2011-05-17	2013-01-03	Novartis Ag	Derivados sustituidos de indol
WO2012167423A1 (en)	2011-06-08	2012-12-13	Hutchison Medipharma Limited	Substituted pyridopyrazines as novel syk inhibitors
CA2843138C (en) *	2011-07-28	2020-06-02	Rigel Pharmaceuticals, Inc.	New (trimethoxyphenylamino)pyrimidinyl formulations
WO2013052393A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2763974B1 (en)	2011-10-05	2016-09-14	Merck Sharp & Dohme Corp.	Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
WO2013052394A1 (en)	2011-10-05	2013-04-11	Merck Sharp & Dohme Corp.	2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
TW201325593A (zh)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
CA3094793A1 (en)	2011-11-23	2013-05-30	Portola Pharmaceuticals, Inc.	Pyrazine kinase inhibitors
KR102090453B1 (ko)	2012-03-15	2020-03-19	셀젠 카르 엘엘씨	상피 성장 인자 수용체 키나제 억제제의 염
MY169233A (en)	2012-03-15	2019-03-19	Celgene Car Llc	Solid forms of an epidermal growth factor receptor kinase inhibitor
US20150166591A1 (en)	2012-05-05	2015-06-18	Ariad Pharmaceuticals, Inc.	Methods and compositions for raf kinase mediated diseases
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
PT2861608T (pt)	2012-06-19	2019-06-28	Debiopharm Int Sa	Derivados pró-fármacos de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetra-hidro-1,8-naftiridin-3-il)acrilamida
WO2013192128A1 (en)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Imidazolyl analogs as syk inhibitors
WO2013192125A1 (en)	2012-06-20	2013-12-27	Merck Sharp & Dohme Corp.	Pyrazolyl derivatives as syk inhibitors
CN102746337B (zh) *	2012-06-21	2014-12-17	成都苑东药业有限公司	一种2，4-嘧啶二胺类化合物及其制备方法
EP2863915B1 (en)	2012-06-22	2017-12-06	Merck Sharp & Dohme Corp.	SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2013192098A1 (en)	2012-06-22	2013-12-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014031438A2 (en)	2012-08-20	2014-02-27	Merck Sharp & Dohme Corp.	SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
AU2013318182C1 (en)	2012-09-18	2022-01-20	Auspex Pharmaceuticals, Inc.	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9550780B2 (en)	2012-09-18	2017-01-24	Auspex Pharmaceuticals, Inc.	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US9586931B2 (en)	2012-09-28	2017-03-07	Merck Sharp & Dohme Corp.	Triazolyl derivatives as Syk inhibitors
WO2014074421A1 (en) *	2012-11-07	2014-05-15	Merck Sharp & Dohme Corp.	Prodrug bipyridylaminopyridines as syk inhibitors
EP2931281B1 (en)	2012-12-12	2018-01-17	Merck Sharp & Dohme Corp.	Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
WO2014100748A1 (en)	2012-12-21	2014-06-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US9598405B2 (en)	2012-12-21	2017-03-21	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9145387B2 (en)	2013-02-08	2015-09-29	Celgene Avilomics Research, Inc.	ERK inhibitors and uses thereof
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
EP2988749B1 (en)	2013-04-26	2019-08-14	Merck Sharp & Dohme Corp.	Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9745295B2 (en)	2013-04-26	2017-08-29	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EA032920B1 (ru)	2013-12-03	2019-08-30	Оспекс Фармасьютикалз, Инк.	Способы получения соединений бензохинолина
JP6522005B2 (ja) *	2013-12-20	2019-05-29	ライジェルファーマシューティカルズ，インコーポレイテッド	薬学的方法および中間体
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
US9783531B2 (en)	2013-12-20	2017-10-10	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en)	2013-12-20	2021-10-27	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095445A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015131080A1 (en)	2014-02-28	2015-09-03	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
WO2015138273A1 (en)	2014-03-13	2015-09-17	Merck Sharp & Dohme Corp.	2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
US10053455B2 (en) *	2014-03-24	2018-08-21	Ab Science	Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
AU2015303835B2 (en)	2014-08-12	2020-04-09	Monash University	Lymph directing prodrugs
DK3179858T3 (da)	2014-08-13	2019-07-22	Celgene Car Llc	Forme og sammensætninger af en ERK-inhibitor
WO2016138352A1 (en)	2015-02-27	2016-09-01	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
EP3265085B1 (en)	2015-03-06	2022-07-20	Auspex Pharmaceuticals, Inc.	Methods for the treatment of abnormal involuntary movement disorders
US20180296579A1 (en)	2015-04-24	2018-10-18	Rigel Pharmaceuticals, Inc.	Methods of treating ibrutinib-resistant disease
WO2017004134A1 (en)	2015-06-29	2017-01-05	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
JP6802263B2 (ja)	2015-09-02	2020-12-16	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
JP7118888B2 (ja)	2015-09-08	2022-08-16	モナッシュユニバーシティ	リンパ指向性プロドラッグ
US10683308B2 (en)	2015-09-11	2020-06-16	Navitor Pharmaceuticals, Inc.	Rapamycin analogs and uses thereof
PT3364958T (pt)	2015-10-23	2023-04-10	Navitor Pharm Inc	Moduladores de interação sestrina-gator2 e utilizações dos mesmos
EP3389664A4 (en)	2015-12-14	2020-01-08	Raze Therapeutics Inc.	MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
CN118416061A (zh)	2016-02-26	2024-08-02	德彪药业国际股份公司	用于治疗糖尿病足感染的药物
WO2017156179A1 (en)	2016-03-09	2017-09-14	Raze Therapeutics, Inc.	3-phosphoglycerate dehydrogenase inhibitors and uses thereof
ES2883328T3 (es)	2016-03-09	2021-12-07	Raze Therapeutics Inc	Inhibidores de la 3-fosfoglicerato deshidrogenasa y sus usos
CN109153722A (zh)	2016-04-08	2019-01-04	X4 制药有限公司	用于治疗癌症的方法
WO2017223243A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en)	2016-06-21	2017-12-28	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
EP3471727B1 (en)	2016-06-21	2020-12-09	X4 Pharmaceuticals, Inc.	Cxcr4 inhibitors and uses thereof
ES2930198T3 (es)	2016-10-14	2022-12-07	Nimbus Lakshmi Inc	Inhibidores de TYK2 y usos de los mismos
CA3040286A1 (en)	2016-10-21	2018-04-26	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
WO2018089499A1 (en)	2016-11-08	2018-05-17	Navitor Pharmaceuticals, Inc.	PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
EP4035659A1 (en)	2016-11-29	2022-08-03	PureTech LYT, Inc.	Exosomes for delivery of therapeutic agents
WO2018106636A1 (en)	2016-12-05	2018-06-14	Raze Therapeutics, Inc.	Shmt inhibitors and uses thereof
CN110603261A (zh)	2016-12-23	2019-12-20	拜斯科阿迪有限公司	具有新型键结构的肽衍生物
US10624968B2 (en)	2017-01-06	2020-04-21	Bicyclerd Limited	Compounds for treating cancer
CA3055209A1 (en)	2017-03-08	2018-09-13	Nimbus Lakshmi, Inc.	Tyk2 inhibitors, uses, and methods for production thereof
EP3375778A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aryl-piperidine derivatives
EP3375784A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aza-dihydro-acridone derivatives
US11339144B2 (en)	2017-04-10	2022-05-24	Navitor Pharmaceuticals, Inc.	Heteroaryl Rheb inhibitors and uses thereof
CN116370448A (zh)	2017-04-26	2023-07-04	纳维托制药有限公司	Sestrin-gator2相互作用的调节剂及其用途
WO2018197893A1 (en)	2017-04-27	2018-11-01	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
EP3645549A1 (en)	2017-06-26	2020-05-06	BicycleRD Limited	Bicyclic peptide ligands with detectable moieties and uses thereof
EP3658557B1 (en)	2017-07-28	2024-06-05	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors and uses thereof
WO2019025811A1 (en)	2017-08-04	2019-02-07	Bicycletx Limited	SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
US20200283482A1 (en)	2017-08-14	2020-09-10	Bicyclerd Limited	Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019034866A1 (en)	2017-08-14	2019-02-21	Bicyclerd Limited	BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
AU2018324037A1 (en)	2017-08-29	2020-04-16	Monash University	Lymphatic system-directing lipid prodrugs
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
EP3684365A4 (en)	2017-09-22	2021-09-08	Kymera Therapeutics, Inc.	PROTEIN DEGRADATION AGENTS AND USES OF SUCH
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
TWI825046B (zh)	2017-12-19	2023-12-11	英商拜西可泰克斯有限公司	Epha2特用之雙環胜肽配位基
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
WO2019126378A1 (en)	2017-12-19	2019-06-27	Ariya Therapeutics, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
GB201721265D0 (en)	2017-12-19	2018-01-31	Bicyclerd Ltd	Bicyclic peptide ligands specific for EphA2
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	IRAK joints and used in them
US11485743B2 (en)	2018-01-12	2022-11-01	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
WO2019140387A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
SG11202006832YA (en)	2018-01-29	2020-08-28	Merck Patent Gmbh	Gcn2 inhibitors and uses thereof
EP3746075A4 (en)	2018-01-29	2021-09-08	Merck Patent GmbH	GCN2 INHIBITORS AND THEIR USES
IL301120A (en)	2018-02-27	2023-05-01	Artax Biopharma Inc	A history of novel chromium as TCR–NCK interaction inhibitors
BR112020020940A2 (pt)	2018-04-24	2021-03-02	Merck Patent Gmbh	compostos antiproliferação e uso dos mesmos
CN112218865B (zh)	2018-04-24	2024-03-12	沃泰克斯药物股份有限公司	喋啶酮化合物及其用途
ES2982253T3 (es)	2018-06-15	2024-10-15	Janssen Pharmaceutica Nv	Análogos de la rapamicina y usos de los mismos
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en)	2018-06-22	2018-08-08	Bicyclerd Ltd	Peptide ligands for binding to EphA2
EP3817748A4 (en)	2018-07-06	2022-08-24	Kymera Therapeutics, Inc.	TRICYCLIC CRBN LIGANDS AND USES THEREOF
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
JP2022500499A (ja)	2018-09-07	2022-01-04	ピクセラピューティクス，インコーポレイテッド	Ｅｉｆ４ｅ阻害剤およびその使用
CN113271940A (zh)	2018-10-15	2021-08-17	林伯士拉克许米公司	Tyk2抑制剂和其用途
JP2022512779A (ja)	2018-10-23	2022-02-07	バイスクルテクス・リミテッド	二環式ペプチドリガンドおよびその使用
WO2020086816A1 (en)	2018-10-24	2020-04-30	Navitor Pharmaceuticals, Inc.	Polymorphic compounds and uses thereof
US20220000880A1 (en)	2018-11-01	2022-01-06	Rigel Pharmaceuticals, Inc.	Method and composition embodiments for treating acute myeloid leukemia
JP2022516401A (ja)	2018-11-30	2022-02-28	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
US11053241B2 (en)	2018-11-30	2021-07-06	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CA3126034A1 (en)	2019-01-23	2020-07-30	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
WO2020165600A1 (en)	2019-02-14	2020-08-20	Bicycletx Limited	Bicyclic peptide ligand sting conjugates and uses thereof
CA3135569A1 (en)	2019-04-02	2020-10-08	Bicycletx Limited	Bicycle toxin conjugates and uses thereof
SG11202110829YA (en)	2019-04-05	2021-10-28	Kymera Therapeutics Inc	Stat degraders and uses thereof
US11458149B1 (en)	2019-05-31	2022-10-04	Ikena Oncology, Inc.	TEAD inhibitors and uses thereof
TW202118770A (zh)	2019-07-30	2021-05-16	英商拜西可泰克斯有限公司	異質雙環肽複合物
EP4013420B1 (en)	2019-08-14	2023-11-01	Rigel Pharmaceuticals, Inc.	Method of blocking or ameliorating cytokine release syndrome
JP2022548594A (ja)	2019-09-11	2022-11-21	ビンシア・バイオサイエンシーズ・インコーポレイテッド	Ｕｓｐ３０阻害剤及びその使用
WO2021050964A1 (en)	2019-09-13	2021-03-18	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
JP2022554276A (ja)	2019-11-01	2022-12-28	ナビターファーマシューティカルズ，インコーポレイテッド	Ｍｔｏｒｃ１モジュレーターを使用する処置方法
EP4069223A4 (en)	2019-12-05	2023-12-20	Janssen Pharmaceutica NV	RAPAMYCIN ANALOGS AND THEIR USES
MX2022007576A (es)	2019-12-17	2022-09-23	Kymera Therapeutics Inc	Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
AU2020412780A1 (en)	2019-12-23	2022-07-21	Kymera Therapeutics, Inc.	SMARCA degraders and uses thereof
WO2021159021A1 (en)	2020-02-05	2021-08-12	Puretech Lyt, Inc.	Lipid prodrugs of neurosteroids
AR121506A1 (es)	2020-03-03	2022-06-08	Pic Therapeutics Inc	Inhibidores del eif4e y sus usos
BR112022018678A2 (pt)	2020-03-19	2022-11-01	Kymera Therapeutics Inc	Degradadores de mdm2 e usos dos mesmos
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
US20240240255A1 (en)	2020-08-17	2024-07-18	Bicycletx Limited	Bicycle conjugates specific for nectin-4 and uses thereof
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
EP4255895A1 (en)	2020-12-02	2023-10-11	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
WO2022167445A1 (en)	2021-02-02	2022-08-11	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
CA3206501A1 (en)	2021-02-02	2022-08-11	Shaun Abbott	Gpr84 antagonists and uses thereof
IL304905A (en)	2021-02-15	2023-10-01	Kymera Therapeutics Inc	IRAK4 joints and their uses
EP4301756A1 (en)	2021-03-05	2024-01-10	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
WO2022213062A1 (en)	2021-03-29	2022-10-06	Nimbus Saturn, Inc.	Hpk1 antagonists and uses thereof
CA3215081A1 (en)	2021-04-16	2022-10-20	Alfredo C. Castro	Mek inhibitors and uses thereof
KR20240020735A (ko)	2021-05-07	2024-02-15	카이메라 쎄라퓨틱스 인코포레이티드	Cdk2 분해제 및 그 용도
CN113624665A (zh) *	2021-07-30	2021-11-09	中国药科大学	一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
JP2024534127A (ja)	2021-08-25	2024-09-18	ピクセラピューティクス，インコーポレイテッド	ｅＩＦ４Ｅ阻害剤及びその使用
EP4392421A1 (en)	2021-08-25	2024-07-03	PIC Therapeutics, Inc.	Eif4e inhibitors and uses thereof
CA3237696A1 (en)	2021-11-08	2023-05-11	Progentos Therapeutics, Inc.	Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
IL314437A (en)	2022-01-31	2024-09-01	Kymera Therapeutics Inc	IRAK joints and their uses
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof
TW202415650A (zh)	2022-08-02	2024-04-16	英商利米那生物科技有限公司	芳基-三唑基及相關gpr84拮抗劑及其用途
TW202416950A (zh)	2022-08-02	2024-05-01	英商利米那生物科技有限公司	雜芳基甲醯胺及相關gpr84拮抗劑及其用途
TW202416972A (zh)	2022-08-02	2024-05-01	英商利米那生物科技有限公司	經取代之吡啶酮gpr84拮抗劑及其用途
TW202430148A (zh)	2022-11-22	2024-08-01	美商皮克醫療公司	ｅＩＦ４Ｅ抑制劑及其用途

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1029650B (de)	1954-03-15	1958-05-08	Franz Litzka	Zusatzeinrichtung fuer Schneidmotoren
GR80171B (en)	1983-08-29	1985-01-02	Ciba Geigy Ag	N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use
DE3618353A1 (de)	1986-05-31	1987-12-03	Hoechst Ag	Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen
JPS6312485A (ja)	1986-06-25	1988-01-19	日立米沢電子株式会社	トレ−
IE63502B1 (en)	1989-04-21	1995-05-03	Zeneca Ltd	Aminopyrimidine derivatives useful for treating cardiovascular disorders
JPH03127790A (ja)	1989-10-11	1991-05-30	Morishita Pharmaceut Co Ltd	Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
TW224941B (pl)	1989-11-08	1994-06-11	Yamanouchi Pharma Co Ltd
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
DE4029650A1 (de)	1990-09-19	1992-03-26	Hoechst Ag	2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
US5430148A (en) *	1992-03-31	1995-07-04	Agouron Pharmaceuticals, Inc.	Antiproliferative quinazolines
SK47096A3 (en)	1993-10-12	1996-10-02	Du Pont Merck Pharma	1n-alkyl-n-arylpyrimidinamines and derivatives thereof
IL112290A (en)	1994-01-12	1999-01-26	Novartis Ag	Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
TW440563B (en)	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
US6004985A (en)	1996-10-09	1999-12-21	Berlex Laboratories, Inc.	Thio acid derived monocylic N-heterocyclics as anticoagulants
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
US6093820A (en) *	1997-10-02	2000-07-25	Taro Pharmaceutical Industries Ltd.	Method and reagents for N-alkylating ureides
GB9723859D0 (en)	1997-11-12	1998-01-07	Zeneca Ltd	Compound,composition and use
ES2308821T3 (es)	1997-12-15	2008-12-01	Astellas Pharma Inc.	Nuevos derivados de pirimidin-5-carboxamida.
US6436989B1 (en) *	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
CA2317008C (en) *	1997-12-31	2009-01-20	The University Of Kansas	Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
IL137922A0 (en)	1998-02-17	2001-10-31	Tularik Inc	Anti-viral pyrimidine derivatives
KR100699514B1 (ko)	1998-03-27	2007-03-26	얀센 파마슈티카 엔.브이.	Ｈｉｖ를 억제하는 피리미딘 유도체
DE69943247D1 (de)	1998-03-27	2011-04-14	Janssen Pharmaceutica Nv	HIV hemmende Pyrimidin Derivate
EP1107957B1 (en)	1998-08-29	2006-10-18	AstraZeneca AB	Pyrimidine compounds
DE19851421A1 (de)	1998-11-07	2000-05-11	Boehringer Ingelheim Pharma	Neue Pyrimidine, deren Herstellung und Verwendung
EA004049B1 (ru)	1998-11-10	2003-12-25	Янссен Фармацевтика Н.В.	Пиримидины, ингибирующие репликацию вич
US6127376A (en)	1998-12-04	2000-10-03	Berlex Laboratories, Inc.	Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
DE19917785A1 (de)	1999-04-20	2000-10-26	Bayer Ag	2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
DE19945982A1 (de)	1999-09-24	2001-03-29	Knoll Ag	Geschwindigkeitsbestimmte Partikel
EE04991B1 (et)	1999-09-24	2008-04-15	Janssen Pharmaceutica N.V.	Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
ATE318267T1 (de)	1999-09-30	2006-03-15	Neurogen Corp	Einige alkylendiamin-substituierte heterocyclen
AU1026901A (en)	1999-10-29	2001-05-08	Syngenta Participations Ag	Novel herbicides
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
ES2335265T3 (es)	1999-12-28	2010-03-24	Pharmacopeia, Inc.	Inhibidores de citoquina, especialmente de tnf-alfa.
US6362172B2 (en)	2000-01-20	2002-03-26	Bristol-Myers Squibb Company	Water soluble prodrugs of azole compounds
US20030004174A9 (en)	2000-02-17	2003-01-02	Armistead David M.	Kinase inhibitors
GB0004886D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
EP1278742B1 (en) *	2000-04-27	2004-12-15	Basilea Pharmaceutica AG	Chromenylmethylpyrimidinediamines as antibacterial agents
CA2407754C (en)	2000-05-08	2009-09-15	Janssen Pharmaceutica N.V.	Prodrugs of hiv replication inhibiting pyrimidines
JP5230050B2 (ja)	2000-05-08	2013-07-10	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｈｉｖ複製阻害剤
GB0016877D0 (en)	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
WO2002022602A2 (en)	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Triazole compounds useful as protein kinase inhibitors
US6448401B1 (en) *	2000-11-20	2002-09-10	Bristol-Myers Squibb Company	Process for water soluble azole compounds
ES2266095T3 (es)	2000-12-21	2007-03-01	Vertex Pharmaceuticals Incorporated	Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
PT1343782E (pt)	2000-12-21	2009-06-29	Smithkline Beecham Corp	Pirimidinoaminas como moduladores de angiogénese
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
MXPA03007266A (es)	2001-02-20	2003-12-04	Astrazeneca Ab	2-arilamino-pirimidinas para tratamiento de desordenes relacionados a glucogeno-sintasa cinasa-3(gsk3).
MXPA03010810A (es)	2001-05-29	2004-03-22	Schering Ag	Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
WO2002102800A1 (en)	2001-06-15	2002-12-27	Vertex Pharmaceuticals Incorporated	5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
US7087614B2 (en)	2001-06-19	2006-08-08	Bristol-Myers Squibb Co.	Pyrimidine inhibitors of phosphodiesterase (PDE) 7
WO2003000186A2 (en)	2001-06-21	2003-01-03	Ariad Pharmaceuticals, Inc.	Novel phenylamino-pyrimidines and uses thereof
JP4510442B2 (ja)	2001-06-26	2010-07-21	ブリストル−マイヤーズスクイブカンパニー	ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en)	2001-09-26	2003-04-03	Bayer Corporation	2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en)	2001-09-28	2003-05-15	Bayer Pharmaceuticals Corporation	Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
EP2332924A1 (de)	2001-10-17	2011-06-15	Boehringer Ingelheim Pharma GmbH & Co. KG	Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
EP1453516A2 (de)	2001-10-17	2004-09-08	Boehringer Ingelheim Pharma GmbH & Co.KG	5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
JP2003127790A (ja)	2001-10-25	2003-05-08	Nippon Soken Inc	メータ装置
CN100354267C (zh)	2001-11-28	2007-12-12	英国技术集团国际有限公司	含有含氮芳香杂环化合物的阿耳茨海默氏病的预防药或治疗药或者淀粉样蛋白纤维化抑制剂
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
AU2002367172A1 (en)	2001-12-21	2003-07-15	Bayer Pharmaceuticals Corporation	2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US6924290B2 (en)	2002-01-23	2005-08-02	Bayer Pharmaceuticals Corporation	Rho-kinase inhibitors
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
US6998391B2 (en)	2002-02-07	2006-02-14	Supergen.Inc.	Method for treating diseases associated with abnormal kinase activity
JP2005522438A (ja)	2002-02-08	2005-07-28	スミスクラインビーチャムコーポレーション	ピリミジン化合物
EP1487824B1 (en)	2002-03-01	2007-06-20	SmithKline Beecham Corporation	Diamino-pyrimidines and their use as angiogenesis inhibitors
AU2003212282A1 (en)	2002-03-11	2003-09-22	Schering Aktiengesellschaft	Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
US7288547B2 (en)	2002-03-11	2007-10-30	Schering Ag	CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
GEP20074230B (en)	2002-03-20	2007-11-12	Bristol Myers Squibb Co	Phosphate prodrugs of fluorooxindoles
AU2003301758A1 (en)	2002-05-06	2004-05-25	Bayer Pharmaceuticals Corporation	Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders
WO2003095448A1 (en)	2002-05-06	2003-11-20	Bayer Pharmaceuticals Corporation	Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AR039540A1 (es)	2002-05-13	2005-02-23	Tibotec Pharm Ltd	Compuestos microbicidas con contenido de pirimidina o triazina
EP1507779A1 (en)	2002-05-30	2005-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of jak and cdk2 protein kinases
AU2003276125B2 (en)	2002-06-17	2007-05-17	Smithkline Beecham Corporation	Chemical process
US7449456B2 (en)	2002-06-28	2008-11-11	Astellas Pharma, Inc.	Diaminopyrimidinecarboxamide derivative
US7517886B2 (en) *	2002-07-29	2009-04-14	Rigel Pharmaceuticals, Inc.	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003249539A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
JP4741948B2 (ja)	2002-08-14	2011-08-10	バーテックスファーマシューティカルズインコーポレイテッド	プロテインキナーゼインヒビターおよびそれらの使用
DE60330895D1 (de)	2002-11-01	2010-02-25	Vertex Pharma	Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
CA2507406A1 (en)	2002-11-05	2004-05-21	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of jak and other protein kinases
RS20050363A (en)	2002-11-28	2007-11-15	Schering Aktiengesellschaft,	Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2003289330A1 (en)	2002-12-13	2004-07-09	Kyowa Hakko Kogyo Co., Ltd.	Preventives and/or remedies for central diseases
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US20070021449A1 (en)	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
CL2004000303A1 (es)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
EP1597251B1 (en)	2003-02-20	2009-06-10	SmithKline Beecham Corporation	Pyrimidine compounds
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
CA2524221A1 (en)	2003-04-30	2004-11-18	The Institutes For Pharmaceutical Discovery, Llc	Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
GB0311276D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
WO2005007621A2 (en)	2003-05-30	2005-01-27	Rigel Pharmaceuticals, Inc.	Ubiquitin ligase inhibitors
US20070161637A1 (en)	2003-07-22	2007-07-12	Neurogen Corporation	Substituted pyridin-2-ylamine analogues
US7442698B2 (en)	2003-07-24	2008-10-28	Amgen Inc.	Substituted heterocyclic compounds and methods of use
DK1656372T3 (da)	2003-07-30	2013-07-01	Rigel Pharmaceuticals Inc	2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
CA2533474A1 (en)	2003-07-30	2005-02-10	Shudong Wang	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
DE602004032446D1 (de)	2003-08-07	2011-06-09	Rigel Pharmaceuticals Inc	2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
AU2004264382A1 (en)	2003-08-15	2005-02-24	Irm Llc	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
MXPA06003054A (es)	2003-09-18	2006-05-31	Novartis Ag	2,4-di-(fenil-amino)-pirimidinas utiles en el tratamiento de trastornos proliferativos.
DE10349423A1 (de)	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
AR047496A1 (es)	2003-11-28	2006-01-25	Novartis Ag	Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
MY141255A (en)	2003-12-11	2010-03-31	Memory Pharm Corp	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2005063722A1 (en)	2003-12-19	2005-07-14	Rigel Pharmaceuticals, Inc.	Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
US7745625B2 (en) *	2004-03-15	2010-06-29	Bristol-Myers Squibb Company	Prodrugs of piperazine and substituted piperidine antiviral agents
EP1763514A2 (en)	2004-05-18	2007-03-21	Rigel Pharmaceuticals, Inc.	Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20060047135A1 (en)	2004-08-30	2006-03-02	Chadwick Scott T	Process for preparing chloromethyl di-tert-butylphosphate
EP1786783A1 (en)	2004-09-01	2007-05-23	Rigel Pharmaceuticals, Inc.	Synthesis of 2,4-pyrimidinediamine compounds
WO2006034872A1 (de)	2004-09-29	2006-04-06	Bayer Schering Pharma Aktiengesellschaft	Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
CA2584808A1 (en)	2004-10-29	2006-05-11	Rigel Pharmaceuticals, Inc.	Substituted pyridines with activity on syk kinase
SI1814878T1 (sl)	2004-11-24	2012-06-29	Rigel Pharmaceuticals Inc	Spojine spiro-2,4-pirimidindiamina in njihova uporaba
US7442716B2 (en)	2004-12-17	2008-10-28	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
JP5208516B2 (ja)	2004-12-30	2013-06-12	エグゼリクシス，インコーポレイテッド	キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
PL1856135T3 (pl)	2005-01-19	2010-05-31	Rigel Pharmaceuticals Inc	Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
EP1883302A4 (en)	2005-05-03	2009-05-20	Rigel Pharmaceuticals Inc	JAK KINASE HEMMER AND ITS USE
JP5225079B2 (ja)	2005-06-08	2013-07-03	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2607901C (en)	2005-06-13	2016-08-16	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
JP2009501711A (ja)	2005-07-11	2009-01-22	サノフイ−アベンテイス	新規２，４−ジアニリノピリミジン誘導体、その調製、医薬、医薬組成物としての、特に、ｉｋｋ阻害剤としてのそれらの使用
TW200740838A (en)	2005-07-28	2007-11-01	Intervet Int Bv	Novel benzimidazole (thio)carbamates with antiparasitic activity and the synthesis thereof
WO2007032263A1 (ja)	2005-09-13	2007-03-22	Eisai R & D Management Co., Ltd.	安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法
US7508791B2 (en)	2005-10-31	2009-03-24	Kyocera Corporation	Wireless communication coding and transmission systems and methods
CA2627242A1 (en)	2005-10-31	2007-05-10	Rigel Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory disorders
US7713987B2 (en)	2005-12-06	2010-05-11	Rigel Pharmaceuticals, Inc.	Pyrimidine-2,4-diamines and their uses
TW200736232A (en)	2006-01-26	2007-10-01	Astrazeneca Ab	Pyrimidine derivatives
WO2007085540A1 (en)	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
KR101411695B1 (ko)	2006-02-17	2014-07-03	리겔 파마슈티칼스, 인크.	자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
CA2642229C (en)	2006-02-24	2015-05-12	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US7631707B2 (en) *	2006-03-29	2009-12-15	Cyrus Solutions Corporation	Shape memory alloy actuated steerable drilling tool
US20090192158A1 (en)	2006-05-02	2009-07-30	Stacia Kargman	Methods for Treating or Preventing Neoplasias
US7776855B2 (en)	2006-07-27	2010-08-17	Janssen Pharmaceutica N.V.	Antimicrobial oxazolidinone prodrugs
US8193197B2 (en)	2006-10-19	2012-06-05	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2008118822A1 (en)	2007-03-23	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
WO2008118823A2 (en)	2007-03-26	2008-10-02	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US9815606B2 (en)	2015-04-29	2017-11-14	Barton Group, Inc.	Flexible stand-up pouch container for flowable products

2006
- 2006-01-19 PL PL06718943T patent/PL1856135T3/pl unknown
- 2006-01-19 AT AT06718943T patent/ATE451381T1/de active
- 2006-01-19 CA CA2591948A patent/CA2591948C/en active Active
- 2006-01-19 RU RU2007131430/04A patent/RU2416616C2/ru active
- 2006-01-19 NZ NZ555947A patent/NZ555947A/en unknown
- 2006-01-19 SI SI200630571T patent/SI1856135T1/sl unknown
- 2006-01-19 EP EP06718943A patent/EP1856135B1/en active Active
- 2006-01-19 WO PCT/US2006/001945 patent/WO2006078846A1/en active Application Filing
- 2006-01-19 BR BRPI0606318A patent/BRPI0606318B8/pt active IP Right Grant
- 2006-01-19 CN CN2006800026433A patent/CN101115761B/zh active Active
- 2006-01-19 US US11/337,049 patent/US7449458B2/en active Active
- 2006-01-19 DE DE602006010979T patent/DE602006010979D1/de active Active
- 2006-01-19 MX MX2007007189A patent/MX2007007189A/es active IP Right Grant
- 2006-01-19 JP JP2007552272A patent/JP4801096B2/ja active Active
- 2006-01-19 ES ES06718943T patent/ES2337496T3/es active Active
- 2006-01-19 PT PT06718943T patent/PT1856135E/pt unknown
- 2006-01-19 EP EP09015170A patent/EP2161275A1/en not_active Withdrawn
- 2006-01-19 KR KR1020077018898A patent/KR101278397B1/ko active IP Right Grant
- 2006-01-19 DK DK06718943.1T patent/DK1856135T3/da active
- 2006-01-19 AU AU2006206458A patent/AU2006206458B2/en active Active
- 2006-06-14 US US11/453,731 patent/US7538108B2/en active Active
- 2006-10-05 US US11/539,074 patent/US7563892B1/en active Active
2007
- 2007-06-13 IL IL183890A patent/IL183890A/en active IP Right Grant
- 2007-06-14 MX MX2012002964A patent/MX346822B/es unknown
- 2007-08-14 NO NO20074179A patent/NO339146B1/no active Protection Beyond IP Right Term
2008
- 2008-03-13 HK HK08102972.0A patent/HK1108896A1/xx unknown
- 2008-11-10 US US12/268,218 patent/US7989448B2/en active Active
2010
- 2010-03-09 CY CY20101100218T patent/CY1109888T1/el unknown
2011
- 2011-06-30 US US13/174,091 patent/US8211888B2/en active Active
- 2011-07-08 JP JP2011152261A patent/JP2011236234A/ja active Pending
2012
- 2012-01-12 US US13/349,194 patent/US8211889B2/en active Active
- 2012-05-18 US US13/475,037 patent/US8476263B2/en active Active
2013
- 2013-06-04 US US13/909,858 patent/US8785437B2/en active Active
2014
- 2014-06-20 US US14/310,312 patent/US9266912B2/en active Active
2016
- 2016-01-13 US US14/995,027 patent/US9532998B2/en active Active
- 2016-11-23 US US15/360,025 patent/US20170291909A1/en not_active Abandoned
2018
- 2018-11-28 US US16/203,108 patent/US10577381B2/en active Active
2020
- 2020-03-02 US US16/806,541 patent/US20200270271A1/en active Pending
- 2020-04-28 NL NL301039C patent/NL301039I2/nl unknown
- 2020-05-08 LU LU00153C patent/LUC00153I2/fr unknown
- 2020-05-13 NO NO2020010C patent/NO2020010I1/no unknown
- 2020-05-19 FI FIC20200014C patent/FIC20200014I1/fi unknown
- 2020-05-19 HU HUS2000011C patent/HUS2000011I1/hu unknown
- 2020-06-04 LT LTPA2020507C patent/LTC1856135I2/lt unknown
- 2020-06-10 CY CY2020012C patent/CY2020012I2/el unknown

Also Published As

Publication number	Publication date
US9532998B2 (en)	2017-01-03
US7563892B1 (en)	2009-07-21
MX346822B (es)	2017-03-28
US20140357598A1 (en)	2014-12-04
CY1109888T1 (el)	2014-09-10
CN101115761B (zh)	2012-07-18
US8211888B2 (en)	2012-07-03
US20060234983A1 (en)	2006-10-19
US20060211657A1 (en)	2006-09-21
ATE451381T1 (de)	2009-12-15
US8211889B2 (en)	2012-07-03
ES2337496T3 (es)	2010-04-26
CN101115761A (zh)	2008-01-30
JP2011236234A (ja)	2011-11-24
IL183890A0 (en)	2007-10-31
CY2020012I1 (el)	2020-11-25
LTPA2020507I1 (lt)	2020-06-25
SI1856135T1 (sl)	2010-04-30
CA2591948C (en)	2013-11-12
US9266912B2 (en)	2016-02-23
RU2416616C2 (ru)	2011-04-20
PT1856135E (pt)	2010-02-26
US20090124580A1 (en)	2009-05-14
JP4801096B2 (ja)	2011-10-26
US10577381B2 (en)	2020-03-03
US7449458B2 (en)	2008-11-11
JP2008527048A (ja)	2008-07-24
EP2161275A1 (en)	2010-03-10
EP1856135B1 (en)	2009-12-09
US20190292197A1 (en)	2019-09-26
DK1856135T3 (da)	2010-04-12
NZ555947A (en)	2010-11-26
US8785437B2 (en)	2014-07-22
US20120108810A1 (en)	2012-05-03
NO20074179L (no)	2007-10-18
AU2006206458A1 (en)	2006-07-27
US20170291909A1 (en)	2017-10-12
US20110319613A1 (en)	2011-12-29
NL301039I2 (nl)	2020-05-12
US20130338357A1 (en)	2013-12-19
LTC1856135I2 (lt)	2021-07-12
CY2020012I2 (el)	2020-11-25
KR101278397B1 (ko)	2013-06-25
BRPI0606318A2 (pt)	2009-06-16
BRPI0606318B8 (pt)	2021-05-25
US20120232036A1 (en)	2012-09-13
MX2007007189A (es)	2010-09-28
US20160136191A1 (en)	2016-05-19
IL183890A (en)	2012-04-30
HUS2000011I1 (hu)	2020-06-29
BRPI0606318B1 (pt)	2021-02-02
RU2007131430A (ru)	2009-02-27
DE602006010979D1 (de)	2010-01-21
FIC20200014I1 (fi)	2020-05-19
US7538108B2 (en)	2009-05-26
LUC00153I1 (pl)	2020-05-08
KR20070098926A (ko)	2007-10-05
AU2006206458B2 (en)	2012-10-25
NO339146B1 (no)	2016-11-14
US7989448B2 (en)	2011-08-02
US20200270271A1 (en)	2020-08-27
HK1108896A1 (en)	2008-05-23
CA2591948A1 (en)	2006-07-27
LUC00153I2 (pl)	2021-02-15
NL301039I1 (nl)	2020-04-29
US8476263B2 (en)	2013-07-02
NO2020010I1 (no)	2020-05-13
EP1856135A1 (en)	2007-11-21
WO2006078846A1 (en)	2006-07-27

Publication	Publication Date	Title
HUS2000011I1 (hu)	2020-06-29	A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
HK1133257A1 (pl)	2010-03-19
MX2007005933A (es)	2007-06-20	Compuestos de acetamida como fungicidas.
MXPA05009682A (es)	2006-01-27	Metodos de radiofluorinacion de vectores biologicamente activos.
TW200734303A (en)	2007-09-16	Organic compounds
TNSN07222A1 (en)	2008-11-21	Nematicidal compositions
TW200715966A (en)	2007-05-01	Synergistic fungicidal active compound combinations
HK1145172A1 (en)	2011-04-08	(aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
IN2012DN02609A (pl)	2015-09-04
MY143677A (en)	2011-06-30	Amide prodrug of gemcitabine, compositions and use thereof
TW200621160A (en)	2006-07-01	Anti-termite agent
TW200637806A (en)	2006-11-01	2-alkylcycloalk(en)ylcarboxamides
WO2011009075A3 (en)	2011-09-09	Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
HK1128703A1 (en)	2009-11-06	Neuroprotective compounds and uses thereof
UA91210C2 (ru)	2010-07-12	Пролекарства на основе соединений 2,4-пиримидиндиамина и их применение
TW200615274A (en)	2006-05-16	Chemical compounds
HRP20120434T1 (en)	2012-06-30	4-oxadiazolyl-piperidine compounds and use thereof
AU302041S (en)	2005-06-09	Simple table